Corinne Johnson
Stock Analyst at Goldman Sachs
(2.97)
# 1,335
Out of 5,241 analysts
19
Total ratings
53.33%
Success rate
12.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Neutral | $29 → $32 | $26.53 | +20.62% | 3 | Apr 15, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $28 → $34 | $19.41 | +75.17% | 3 | Apr 1, 2026 | |
| TGTX TG Therapeutics | Maintains: Neutral | $37 → $39 | $39.48 | -1.22% | 1 | Jan 15, 2026 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $30.98 | -41.90% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $12.86 | +55.52% | 2 | Sep 16, 2025 | |
| RNA Atrium Therapeutics | Reinstates: Buy | $55 | $12.95 | +324.71% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $27.04 | +22.04% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $157.21 | +15.77% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $62.93 | -20.55% | 3 | May 14, 2024 |
Immunovant
Apr 15, 2026
Maintains: Neutral
Price Target: $29 → $32
Current: $26.53
Upside: +20.62%
Syndax Pharmaceuticals
Apr 1, 2026
Maintains: Buy
Price Target: $28 → $34
Current: $19.41
Upside: +75.17%
TG Therapeutics
Jan 15, 2026
Maintains: Neutral
Price Target: $37 → $39
Current: $39.48
Upside: -1.22%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $30.98
Upside: -41.90%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $12.86
Upside: +55.52%
Atrium Therapeutics
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $12.95
Upside: +324.71%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $27.04
Upside: +22.04%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $157.21
Upside: +15.77%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $62.93
Upside: -20.55%